- Development of domestic vaccines will boost pharmaceutical industry, but broader rollout will face delays in coming months
- Slow global vaccine exports and low available doses mean mass vaccination unlikely to start until late 2021 or early 2022
- Potential for new outbreaks will sustain risk of reintroduction of local restrictions and ensure international travel remains strictly controlled in coming year
The first phase of clinical trials for Hanoi’s second coronavirus (COVID-19) vaccine Covivac began on 15 March and is expected to last until 20 April. This follows the start of the second phase of clinical trials for its first domestic vaccine, Nanocovax, last month.
Falanx Assynt is a global intelligence consultancy and leading provider of geopolitical, strategic and business risk analysis since 2003. Falanx Assynt is part of Falanx Group Ltd (LON:FLX) which, through its subsidiaries, provides cyber defence and intelligence services to blue chip and government clients worldwide.